Deferiprone NDC 73190-095

NDC codes

FDA NDC Directory

Product NDC (as listed)73190-095Labeler and product segments. Claims need a package NDC.

Product NDC at billing width73190-0095Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
73190-095-01	73190009501	100 TABLET in 1 BOTTLE (73190-095-01)Marketed from Aug 12, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Deferiprone
Generic name (nonproprietary): deferiprone
Active ingredients: Deferiprone — 500 mg/1
Dosage form: Tablet
Route: Oral
Labeler: AvKARE
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 208800
Marketing start: Aug 12, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Iron Chelating Activity (Mechanism)
Identifiers: Product ID 73190-095_58dd1379-c90d-d871-e063-6294a90a174cSPL ID 58dd1379-c90d-d871-e063-6294a90a174cSPL set ID 58dd1370-5042-833f-e063-6394a90a0777RxCUI 389242UNII 2BTY8KH53LUPC 0373190095010
Pharmacologic class: Iron Chelator

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N473190009501 followed by a unit qualifier and the quantity

Package 73190-0095-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 12, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Deferiprone tablets are indicated for the treatment of transfusional iron overload in adult patients with thalassemia syndromes when current chelation therapy is inadequate. Deferiprone tablets are an iron chelator indicated for the treatment of transfusional iron overload in adult patients with thalassemia syndromes when current chelation therapy is inadequate. ( 1 ) Limitations of Use Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia. Limitations of Use Safety and effectiveness have not been established for the treatment of transfusional iron overload in p…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 208800

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 208800
Product	Strength	Form · route	Labeler	Product NDC
Deferiprone	Deferiprone 1000 mg/1	TabletOral	Sun Pharmaceutical Industries, Inc.	51672-4237
Deferiprone	Deferiprone 500 mg/1	TabletOral	Sun Pharmaceutical Industries, Inc.	51672-4196